PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX

Key Points

• PFA Pension Forsikringsaktieselskab bought 1,118,023 shares of Royalty Pharma in Q4 (about $43.6 million), representing roughly 0.19% ownership per its latest 13F filing.
• CFO Terrance P. Coyne sold 34,791 shares at an average of $49.78 under a pre-arranged Rule 10b5-1 plan, and insiders have sold 382,705 shares (~$16.98 million) over the past three months; insiders still own about 18.84% of the company.
• Royalty Pharma declared a quarterly dividend of $0.235 (annualized $0.94, yield ~1.9%; ex-dividend date May 15), and the stock (market cap ~$28.5B, P/E ~36.6) has an average analyst price target of $50.33 with a consensus rating of "Buy."

PFA Pension Forsikringsaktieselskab purchased a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,118,023 shares of the biopharmaceutical company's stock, valued at approximately $43,592,000. PFA Pension Forsikringsaktieselskab owned 0.19% of Royalty Pharma as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC lifted its position in shares of Royalty Pharma by 1.5% in the 3rd quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company's stock worth $656,000 after purchasing an additional 281 shares during the period. Private Trust Co. NA lifted its position in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 288 shares during the period. Hudson Bay Capital Management LP lifted its position in shares of Royalty Pharma by 1.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company's stock worth $1,037,000 after purchasing an additional 289 shares during the period. Merit Financial Group LLC lifted its position in shares of Royalty Pharma by 3.5% in the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company's stock worth $323,000 after purchasing an additional 306 shares during the period. Finally, Larson Financial Group LLC lifted its position in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 306 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 382,705 shares of company stock worth $16,984,870. Insiders own 18.84% of the company's stock.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $49.47 on Friday. The firm has a market capitalization of $28.54 billion, a PE ratio of 36.64, a price-to-earnings-growth ratio of 3.16 and a beta of 0.40. The firm has a fifty day simple moving average of $47.31 and a two-hundred day simple moving average of $42.41. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a 12 month low of $31.97 and a 12 month high of $50.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. The business had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. Analysts forecast that Royalty Pharma PLC will post 5.08 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma's payout ratio is 69.63%.

Wall Street Analysts Forecast Growth

RPRX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 14th. Morgan Stanley lifted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an "overweight" rating in a research note on Friday, April 10th. The Goldman Sachs Group reiterated a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. UBS Group lifted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings upgraded shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $50.33.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.